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Abstract: Co-morbid depression is common in patients with diabetes mellitus and has a 
negative impact on diabetes self-care, adherence to treatment and the development of compli-
cations. Effective treatment of depression has been associated with improvement in metabolic 
parameters. We evaluated the feasibility of a two question screen for co-morbid depression 
in diabetic patients and studied the effect of the serotonin norepinephrine reuptake inhibitor 
antidepressant, milnacipran, on metabolic and psychological parameters in 64 type 2 diabetic 
patients with co-morbid depression. The severity of depression was evaluated using the Beck 
Depression Inventory (BDI). Patients received milnacipran, and diabetes was treated according 
to the guidelines of the Austrian Diabetes Association in a 6-month open label study. Metabolic 
parameters and BDI were measured at baseline and after 1, 3 and 6 months. 46 patients satisfied 
the criteria for an antidepressant response (reduction of baseline BDI score of at least 50%). 
Hemoglobin A1c, fasting blood glucose, body mass index, total and LDL-cholesterol and serum 
triglyceride levels were all significantly decreased in these patients at the end of the study whereas 
in antidepressant non-responders these parameters were not significantly changed. Diagnosis 
and treatment of depression is an important factor for the improvement of metabolic control in 
patients with type 2 diabetes and co-morbid depression.
Keywords: depression, diabetes, milnacipran, metabolic control, metformin
Introduction
Depression is common in patients with diabetes mellitus.1 The prevalence of any 
depression (major depression or minor forms) is significantly higher in patients with 
type 2 diabetes than in those without diabetes, 17.6% versus 9.8% respectively.2 In 
addition, the co-morbidity of diabetes and depression is associated with a significantly 
increased risk of death from all causes, beyond that due to having either diabetes or 
depression alone.3 There is a synergistic interaction between diabetes and depression, 
resulting in decreased metabolic control, a higher incidence of micro- and macro-
angiopathic diabetic late complications and decreased quality of life.3–6 In spite of the 
importance of co-morbid depression for the prognosis of diabetic patients, typically 
there is little diagnostic focus on mood disorders and depression frequently goes 
undetected.
The pathophysiological relationship between co-morbid depression and diabetes 
is poorly understood. As with other severe chronic illnesses, psychological factors 
associated with the hardship of diabetes may trigger or enhance depressive symptoms.7 Neuropsychiatric Disease and Treatment 2009:5 262
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There is, however, evidence to suggest that depression 
may precede and act as a causal factor for weight gain and 
diabetes.8 A relation between obesity and depression has 
been described in several studies.9,10 Approximately 80% 
of diabetic patients are obese or overweight and therefore 
obesity may also play a role in the development of co-morbid 
depression.11,12
Data on the impact of antidepressant therapy on metabolic 
and anthropometric parameters in diabetic patients with 
co-morbid depression are still scarce.13,14 The aim of the 
present study was thus to evaluate the efficacy of long-term 
treatment with the antidepressant, milnacipran, in type 2 
diabetic patients with co-morbid depression by measuring 
in parallel effects on depressive symptoms and metabolic 
parameters. In addition we examined the practicability 
of using a simple two-question screening tool for depres-
sion in the non-psychiatric setting of diabetes outpatient 
departments.
Patients and methods
All patients fulfilled the inclusion criteria of a diagnosis of 
diabetes mellitus type 2 and a depressive disorder. Diabetes 
mellitus was defined according to the diagnostic criteria of the 
American Diabetes Association.15 Depression was detected 
by a simple two-question screen16 (Question 1. During the 
past month, have you often been bothered by feeling down, 
depressed, or hopeless? Question 2: During the past month, 
have you often been bothered by little interest or pleasure 
in doing things?). In the case of a positive answer to both 
questions, the diagnosis of depression was subsequently 
confirmed using the 12-item Major Depression Inventory 
(MDI) questionnaire according to ICD-10 criteria for depres-
sive episode.17 Exclusion criteria were contra-indications 
for either metformin or milnacipran, treatment with an 
antidepressant drug within the last 6 months or significant 
suicidal ideation.
The following parameters were measured at baseline 
and after 6 months’ treatment: fasting blood glucose (fBG), 
hemoglobin A1c (HbA1c), total cholesterol, low-density 
lipoprotein cholesterol (LDL-cholesterol), high-density 
lipoprotein cholesterol (HDL-cholesterol), serum triglyc-
erides, blood pressure and weight. Height was measured at 
baseline. Blood samples were taken after an overnight fast 
of 12 hours. Body mass index (BMI, kg/m2) was calculated 
using body weight measured to the nearest kilogram 
and height measured to the nearest cm. Some additional 
metabolic parameters were also measured at 1 and 3 months 
(data not shown).
The severity of depression at baseline and after 1, 3 and 
6 months treatment was evaluated using the Beck Depression 
Inventory (BDI).18 An antidepressant response was defined as 
a reduction of at least 50% in the baseline BDI score.
Spontaneously reported adverse events were recorded 
at each visit.
This observational study was conducted at seven investi-
gational sites (diabetes outpatient departments) across Austria 
in an open longitudinal manner. As a non-interventional 
observational study, ethics committee was not required by 
Austrian legislation. Patient recruitment started in February 
2006 and the last visit of the last patient was documented in 
November 2007.
Diabetes therapy was performed according to the 
Guidelines of the Austrian Diabetes Association,19 starting 
with metformin at 500 to 2000 mg/day as monotherapy after 
lifestyle adjustment failure. Antidepressant treatment was 
initiated with milnacipran at 25 or 50 mg/day. The initial 
dose and subsequent dose adjustment was at the clinicians’ 
discretion and based on clinical response and the patient’s 
tolerance of the drug.
Statistical analysis
Depression data (Figure 1) were analyzed on an intention to 
treat basis. Other analyses, especially comparative analyses, 
are based on those patients for whom data were available 
at baseline and end-point (observed cases technique). All 
significance values are calculated as two-tailed.
Results
Sixty-four patients were recruited into the study and had a 


















baseline 1 month 3 months
Figure 1 evolution of Beck depression inventory scores throughout the study.
Note:  Values are medians of all 64 patients who started the study (iTT analysis).
Abbreviation: BDi, Beck Depression inventory.Neuropsychiatric Disease and Treatment 2009:5 263
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study, including one because of an adverse event (the patient 
reported nausea after 3 months). Other withdrawals were due 
to lack of compliance (1), patients’ decision (2) and lost to 
follow-up (2). Fifty-eight patients finished the study.
Table 1 shows the baseline demographic and clinical 
characteristics of the 58 patients who completed the trial. 
Fifty-two patients (90%) of the patients had never taken 
antidepressant medication and 47 patients (81%) were 
anti-diabetes drug naive and on lifestyle adjustment therapy 
only. Patients were generally obese and their glycemic 
control was rated as moderate or poor. Metabolic param-
eters at baseline and after 6 months treatment (endpoint) 
are shown in Table 2. Over the duration of the study median 
values showed a statistically significant improvement for 
fBG levels, HbA1c, body weight, BMI, total cholesterol, 
LDL-cholesterol and serum triglycerides. The proportion of 
patients with HbA1c  7% increased significantly from 5.2% 
at baseline to 51.7% after 6 months treatment (p  0.001) 
while the proportion of patients with HbA1c  8% decreased 
significantly from 46.6% at baseline to 6.9% at endpoint.
Figure 1 shows the improvement in BDI scores over the 
duration of the study. After 1 month of treatment 20.3% of 
patients had responded to antidepressant treatment, 51.6% 
after 3 months and 71.9% after 6 months. There was no differ-
ence between responders and non-responders concerning age, 
severity of depression, metabolic control or BMI at baseline. 
Mean dose of milnacipran administered during the final three 
months was significantly higher in responder patients than 
non-responder patients (p  0.05). Metformin doses were 
similar for responders and non-responders (Table 3).
As shown in Table 4, antidepressant-responder patients 
had significant improvements in almost all metabolic and 
anthropometric parameters while non-responders showed 
no significant improvement.
Discussion
Diabetic patients with severe depressive symptoms 
frequently have insufficient metabolic control and poorer diet 
and medication regimen adherence, than patients with less 
severe or no depressive symptoms.20,21 Several studies have 
shown that depression is directly associated with an increased 
risk of diabetic complications, especially retinopathy and 
macrovascular complications.5,6
The management of depression with behavioral therapy 
has been shown to be useful and effective in diabetic patients 
with co-morbid depression.22,23 In Austria, however, access 
to psychotherapy is not widespread because of the relatively 
high cost and the need for long-term treatment in most cases. 
The principal treatment of depression in diabetic patients is, 
therefore, oral antidepressant medication.
Studies with antidepressants have shown variable effects 
on metabolic control.13,14,24–26 In a study with sertraline, 
HbA1c levels were reduced during treatment but did not 
differ between the sertraline and placebo groups.13 In another 
study no significant reduction in HbA1c levels was observed 
in patients treated with fluoxetine or paroxetine although 
depressive symptoms were significantly improved.14,24 Simi-
larly, treatment with escitalopram resulted in a significant 
reduction of depression ratings but only a modest, non-
significant reduction in fBG levels and HbA1c levels.25 With 
bupropion, BMI and HbA1c levels decreased significantly 
over an acute treatment phase with the reduction of depres-
sion severity associated with lower HbA1c levels.26
Diabetes is usually diagnosed when the disease has already 
been present for at least 7 years and the patient is already 
showing signs of micro and/or macro-vascular complications, 
sexual dysfunction and non-alcoholic steatohepatitis. The 
choice of which antidepressant to associate must take into 
account the presence of these symptoms. Ideally, the antide-
pressant should have no influence on body weight, cause no 
interactions with the numerous medications that the patient 
is likely to be taking, produce neither hepatotoxicity nor 
Table 1 characteristics at baseline of patients completing the study
Patients (n) 58
sex distribution – m/f (%) 23/35 (40%/60%)
Median age – years (range) 61 (39–85)
Naïve to depression treatment 52 (90%)
Naïve to diabetes drug treatment 47 (81%)
Table 2 Metabolic parameters at baseline and after 6 months’ 
treatment with milnacipran of patients completing the study
Parameter Baseline 6 months p
fBg (mg/dL) 155.0 113.0 0.0001
hbA1c (% of total hb) 7.9 6.9 0.0001
Body weight (kg) 90.5 84 0.001
BMi (kg/m2) 30.4 28 0.001
Total chol (mg/dL) 199.5 178 0.0001
LDL-chol (mg/dL) 117 108 0.001
hDL-chol (mg/dL) 47.0 48.0 Ns
Triglyc (mg/dL) 190 157 0.001
Notes:   All values are given as the median. p = significance of the difference between 
baseline and 6 month values.
Abbreviations: hbA1c, hemoglobin A1c; fBg, fasting blood glucose; BMi, body 
mass index;   Total chol, total cholesterol; LDL-chol, LDL-cholesterol; hDL-chol, 
hDL-cholesterol;   Triglyc, serum triglycerides.Neuropsychiatric Disease and Treatment 2009:5 264
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cardiovascular or blood pressure effects. It should also cause 
minimal sedation and minimal (or no) sexual dysfunction.
For this reason, in the present study, we chose to use the 
antidepressant, milnacipran. In addition to its good overall 
tolerability,27 it has been demonstrated to be weight neutral, 
to be free of cytochrome P450 drug interactions and cardio-
toxicity and to produce minimal sexual dysfunction.
The reduction in depressive symptoms throughout the 
study was similar to that seen with milnacipran in other 
studies of major depression.28–30 By the end of the study over 
70% of the patients fulfilled the criteria for an “antidepressant 
response”. A dose-response relationship for the antidepres-
sant effect of milnacipran has been reported.31 In the present 
study “antidepressant-responder patients” were treated with 
higher doses than non-responders (Table 3) especially during 
the second half of the treatment period. Dose-escalation was 
at the initiative of the treating physician. Whether a lack of 
dose increase resulted from satisfaction with the effect of the 
lower dose or a worry of intolerance of higher doses was not 
recorded. It is, thus, impossible to judge whether the higher 
dose levels were responsible for their improved depressive 
symptoms of the “responder patients”.
Over the duration of the study all of the measured 
metabolic and anthropometric parameters (with the exception 
of HDL cholesterol) improved significantly (Table 2). In 
particular, the number of patients with HbA1c  8%, a 
common benchmark for the need for intensive therapeutic 
intervention, decreased dramatically.
Separate analysis of the “antidepressant responder” and 
“antidepressant non-responder” groups showed that none of 
the metabolic and anthropometric parameters were signifi-
cantly improved in the non-responder group (Table 4).
These results extend earlier reports that improvement of 
depressive symptoms can lead to sustained improvement in 
HbA1c levels.23–26 Significant reductions of serum triglyceride 
levels and body weight were also seen in antidepressant-
responder patients.
A weakness of the comparison of these two groups is 
the small size of the non-responder group which may have 
prevented certain effects from reaching statistical signifi-
cance. Interestingly the non-responder group had a median 
BMI which was numerically considerably smaller than the 
responder group although the difference was not statistically 
significant. It may be interesting to examine the relationship 
between baseline BMI and response to an antidepressant in a 
larger cohort of diabetic patients with co-morbid depression.
There is evidence that depression is under-recognized in 
patients with diabetes.32 The unfavorable impact of untreated 
Table 3 Mean doses of drugs administered throughout the study
Months 0–1 Months 2–3 Months 4–6
  Miln (mg/day) Met (mg/day) Miln (mg/day) Met (mg/day) Miln (mg/day) Met (mg/day)
Responders (n = 46) 43 1264 72 1674 81 1737
Non-responders (n = 12) 46 1563 56 1700 58* 1742
*p  0.05.
Abbreviations: Miln, milnacipran; Met, metformin.
Table 4 change of metabolic and anthropometric parameters in depression responders and non-responders during milnacipran treatment
Responders n = 46 Non-responders n = 12
  baseline 6 months ∆ baseline 6 months ∆
fBg 153 111*** –42 157 131 –26
hbA1c 8.1 6.9*** –1.2 7.7 7.1 –0.6
Bodyweight 92.0 84.0* –8.0 76.0 76.5 +0.5
BMi 31.3 28.7* –2.6 28.0 28.4 +0.4
Total cholest 199.5 178.0*** –21.5 198.5 182.0 –16.5
LDL 119.0 109.0** –10.0 110.5 95.0 –15.5
hDL 47.0 47.0 0.0 47.0 49.0 +2.0
Triglyc 196.0 159.0* –37.0 151.0 146.0 –5.0
Notes: All values are given as the median. Units are the same as those given in Table 2.
*p  0.05; **p  0.01; ***p  0.001 for the difference between baseline and 6 months.
Abbreviations: fBg, fasting blood glucose; hbA1c, hemoglobin A1c; BMi, body mass index; Total cholest, total cholesterol; LDL, low density lipoprotein bound cholesterol; 
hDL, high density lipoprotein bound cholesterols;   Triglyc, serum triglycerides.Neuropsychiatric Disease and Treatment 2009:5 265
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depression on diabetes care and prognosis has been clearly 
documented.32,33 In particular the incidence of late diabetic 
complications and mortality risk are both elevated in patients 
with co-morbid depression.3,5,6,20,21 The present results 
are consistent with other data and suggest that successful 
treatment of depression results in a parallel improvement 
of diabetic symptoms.13,14,23–26 Diabetes is one of the most 
psychologically and behaviorally demanding of the chronic 
medical illnesses. At least 90% of diabetes management is 
conducted by the patient himself. The presence of co-morbid 
depression can reduce motivation for self-care resulting in 
an even more unfavorable or even potentially fatal course 
of diabetes.34 Although most physicians are aware of the 
importance of detecting co-morbid depression in patients 
with diabetes many of them find it difficult in practice. Most 
diagnostic tools for screening depression are complicated, 
time-consuming and often require at least some psychiatric 
training. A number of questionnaires have been developed 
to help identify depression in the primary care setting. These 
are frequently time consuming and therefore not widely used 
in clinical practice. With this limitation in mind, a simple 
two-question screen has been developed.16 It is based on the 
essential criteria of a depressive episode, a period of at least 
2 weeks during which there is either depressed mood and/or 
the loss of interest or pleasure in nearly all activities. This 
two-question screen (Question 1. During the past month, 
have you often been bothered by feeling down, depressed, 
or hopeless? Question 2: During the past month, have you 
often been bothered by little interest or pleasure in doing 
things?) has been found to be an effective means of identify-
ing subjects with depression. A “no” response to both of the 
two questions made depression highly unlikely. For patients 
who answer yes to either of the questions, other symptoms 
should be elicited, to confirm diagnosis of depression. Our 
use of this instrument in a non-psychiatric setting, diabetes 
departments of general hospitals, confirmed its simplicity of 
use and its ready acceptance by the medical personnel. Of the 
patients screened, there were no “false positives”, patients 
identified as possibly depressive who were subsequently 
found not to have depressive symptoms. The use of this 
simple instrument should be encouraged.
The study made an in depth investigation of a large 
number of parameters of a relatively long period of time. The 
study, however, has some methodological weaknesses. It was 
not a randomized, double-blind design and the cohort was 
relatively small especially the non-responder group. In addi-
tion the dose of milnacipran was not closely controlled and 
an effect of different doses cannot be completely ruled out. 
Nevertheless the fact that (with the single exception of HDL 
cholesterol) all of the parameters were improved in the anti-
depressant responder group whereas none of the parameters 
were improved in the non-responder group suggests that the 
findings are probably qualitatively reliable. Clearly a larger, 
randomized trial is warranted.
Long-term treatment of type 2 diabetic patients with 
co-morbid depression with milnacipran results in a clear 
improvement in both depressive symptoms and metabolic 
parameters. Furthermore, patients who did not respond to the 
antidepressant showed no improvement in metabolic param-
eters despite receiving diabetes treatment as recommended 
by international guidelines. Although the present results are 
insufficient to conclude on the necessity of an improvement 
of depressive symptoms in order for metabolic parameters to 
improve this remains a viable working hypothesis. Our results 
thus underline the importance of screening ALL diabetic 
patients for depression with, for example, the simple two-
question screen. For patients with co-morbid depression treat-
ment with an effective antidepressant drug such as milnacipran, 
should be immediately initiated in parallel with diabetes treat-
ment as recommended by international guidelines.
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